NCT03899428View on ClinicalTrials.gov

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Durvalumab

Durvalumab 1500 mg IV (intravenous infusion)

DRUG

Sorafenib

Prescribed by physician.

DRUG

Lenvatinib

Prescribed by physician.

DRUG

Regorafenib

Prescribed by physician.

DRUG

Cabozantinib

Prescribed by physician.

Trial Locations (1)

Unknown

RECRUITING

Humanity & Health Research Centre, Hong Kong

All Listed Sponsors

lead

Humanity & Health Medical Group Limited

OTHER

NCT03899428 - Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | Biotech Hunter | Biotech Hunter